Background. Because antiretrovirals are becoming increasingly available in developing countries, we reviewed the findings of studies that have documented highly active antiretroviral therapy (HAART) use in Africa to identify lessons learned. With the World Health Organization (WHO) guidelines used as a frame of reference, we assessed the feasibility of implementing such programs in Africa. Moreover, clinical and laboratory outcomes were compiled to determine the effectiveness of HAART programs.
Of the 39.4 million people living with HIV/AIDS globally, the Joint United Nations Programme on HIV/ AIDS estimates that 25.4 million affected persons reside in sub-Saharan Africa [1] . Population projection models have been used to predict that, if 25% of patients in this region were treated with HAART, up to 1.3 million incident infections could be prevented after 5 years [2] . Despite the apparent momentum surrounding delivery of antiretroviral therapy (ART) to resourcepoor settings, the World Health Organization (WHO) recently estimated that only ∼150,000 (∼4%) of the use on the African continent to identify the lessons learned from the experience to date. In turn, we evaluated the clinical efficacy of these programs by comparing outcomes to those of industrialized nations. Moreover, we used the WHO guidelines as a frame of reference for drawing conclusions regarding the feasibility of implementing such programs in Africa.
METHODS
We identified all studies published up until February 2005 that assessed HAART use among HIV-positive patients in Africa.
To identify these studies, we conducted computerized searches of the PubMed and Academic Search Premier databases. We used the following keywords: "antiretroviral," "HIV treatment," and "Africa," as well as the names of individual countries.
Given that the published literature is generally a few years behind actual field experience, we also included relevant posters and presentations from 3 major recent AIDS conferences. We hand-searched the abstracts from the Second International AIDS Society Conference on HIV Pathogenesis and Treatment in Paris (2003) , the XVth International AIDS Conference in Bangkok (2004) , and the 10th-12th Conferences on Retroviruses and Opportunistic Infections (2003) (2004) (2005) . We were careful to note the several times in which several articles were published using the data from a single, on-going study. When this occurred, we included the publications that contained the most recent and/or most complete data.
Data analysis primarily consisted of calculating ranges and measures of central tendency. Mean weighted retention and the mean weighted percentage of subjects who developed drug resistance were calculated using the following formula:
, where n is the size of the study.
(percentage of casesϫ n)/ n
RESULTS
We identified twenty-eight articles and conference abstracts that featured observational studies of HAART cohorts in Africa; 14 different African countries were represented (tables 1 and 2). The majority of data collected for these studies came from patients who were receiving drugs through national government or international initiatives. Sample sizes ranged from 20 to 1266 patients, with a median of 139 patients receiving antiretroviral drugs. Most studies began observing patients at the initiation of treatment and observed them for ∼6 months of treatment. A number of common outcome measures were identified, including immunologic (CD4 cell count) and virologic (plasma viral load) markers, clinical manifestations (mortality, opportunistic infections, and weight trend), adherence levels, and development of resistance.
These studies set forth general objectives of determining (1) the effectiveness of HAART, in terms of clinical and laboratory outcomes (i.e., CD4 cell count, viral load, weight trends, opportunistic infections, and mortality); and (2) the feasibility of HAART, in terms of adherence, cohort retention, and costs. A few examined the benefits of once-daily treatment and use of generic versions of drugs [6] [7] [8] [9] [10] . One study from South Africa observed a cohort to determine the effectiveness of concurrent tuberculosis and HIV therapy [11] .
Features of program scale-up. In all included studies, the majority of patients (74.5%) received a HAART regimen consisting of 2 nucleoside reverse-transcriptase inhibitors (NRTIs) with a nonnucleoside reverse-transcriptase inhibitor (NNRTI). The most popular regimen contained zidovudine, lamivudine, and either nevirapine or efavirenz. Other NRTIs administered included stavudine and, in a few cases, didanosine. Another 10% of patients received a HAART regimen that included a protease inhibitor (PI). One study employed a nucleotide analogue regimen consisting of zidovudine, lamivudine, and tenofovir [12] . Overall, 6052 (96.4%) of 6278 subjects were receiving HAART, whereas just 3.6% took unknown or dual-drug regimens.
All studies employed standard laboratory tests used in industrialized settings, including determination of CD4 cell counts and viral loads. Although a few studies implemented alternative monitoring methods, such as total lymphocyte count or complete blood cell count, there were never used as surrogates to the standard evaluative tests [7, 18, 19] . No surrogate monitoring methods were used. Six of the 16 studies that described the frequency of CD4 cell count monitoring reported testing patients at baseline and 6 months later (if only 1 data point was collected) or every 6 months thereafter [7, 9, [13] [14] [15] [16] . The other 10 studies determined CD4 cell counts as often as monthly to every 3 months [6, 8, 11, 12, [17] [18] [19] [20] [21] [22] .
Clinical outcomes. In all cases, clinical outcomes improved. Among the 14 studies that reported on weight trends, the median weight gain was 5.0 kg by the study end (range, 1.5-10.7 kg) [6, 8, 15, [17] [18] [19] [20] [21] [23] [24] [25] [26] [27] [28] . The median mortality rate was 7.4% (range, 0%-27%) [6-18, 20, 21, 23-27, 29-32] . The study that accounted for the highest mortality rate of 27% required its patients to pay for medication, and the authors admitted that safety and efficacy became compromised as a result. Three studies presented the probability of survival at the ends of their investigations, which ranged from 70% to 86.3% [14, 15, 28] .
Toxicity was reported in 17 studies [6-8, 11, 16-21, 23, 24, 26, 27, 30, 31, 33] . Adverse events occurred in 14.3%-80.2% of patients in 8 studies. Three studies reported that 10%-62% of patients experienced specific types of adverse events, with dizziness, anemia, rash, neutropenia, and peripheral neuropathies occurring most frequently.
Finally, 9 studies tracked the emergence of opportunistic infections. Five studies reported that 5%-15% of patients had developed either Centers for Disease Control and Prevention category C HIV-related events, AIDS-defining illnesses, or op- portunistic infections generally [7, 16, 19, 21, 23] . In the latter case, the opportunistic infections that most commonly emerged were tuberculosis and candidiasis. Thirty percent of Senegalese patients taking a once-daily regimen were hospitalized for opportunistic infections [6] . Two other studies found that ∼5% of patients had to change treatments or withdraw from the study as a result of tuberculosis [17, 20] . A final study determined that opportunistic infections decreased by 68% due to HAART [26] . Laboratory outcomes. CD4 cell count determinations and viral load tests were the standard laboratory assessments used to determine immunological and virological improvements, respectively. Increases in the CD4 cell count ranged from 74 to 440 cells/mm 3 at the studies' ends, with median and mean increases of 138.6 and 165.9 cells/mm 3 , respectively. Only 5 of the 22 studies that reported CD4 cell count data found an increase of !100 cells/mm 3 over the duration of treatment follow-up [7, 8, 13, 16, 22] .
Measures of viral load undetectability ranged from !50 to !500 copies/mL. In the 21 studies that reported viral load outcomes, the percentage of patients who had viral loads that were less than the cutoff values by the end of the study varied from 32% to 95%, with a median of 73% of patients achieving undetectability [6-17, 20, 21, 24, 27-29, 31-33] . Adherence to treatment. Adherence to treatment was highlighted as an issue in 10 studies. The percentage of patients who took у95% of treatment doses ranged from 68% to 99% [6-8, 14, 17, 24] . Another study reported that 87% of patients had taken 180% of their medication, whereas a South African studying employing directly observed therapy (DOT) for concurrent tuberculosis/HIV treatment found a median of 1 missed visit per patient [11, 21] . Oyugi et al. [9] determined an average adherence rate of 85% using 4 different methods (pill count, self-report, visual analogue scale, and Medication Event Monitoring System technology). A Nigerian study that compared cohorts aged !55 years with cohorts aged 155 years found that the older patients had an adherence rate of 91%, whereas the younger patients had a reported adherence rate of 76% [19] . None of the 10 studies documented the use of formal adherence-intervention programs.
Retention. Eighteen studies documented retention of cohorts as ranging from 53.8% to 100%, and mean weighted retention among these studies was 79.8% [6-11, 13-15, 18, 20, 21, 23, 26, 27, 29, 31, 32] over a mean duration of follow-up of 12 months. Although the remaining 10 studies did not report retention rates, we may be able to assume that the only patients used in baseline-to-study end analyses were those who successfully completed treatment. Drug resistance. Only 5 studies presented data on drug resistance surveillance. Laurent et al. [14] found that 22 (12.5%) of 176 patients developed resistance to у1 drug, with resistance acquired more quickly to NRTIs, followed by NNRTIs and, finally, PIs. Two studies reported that 1 patient each had developed resistance to lamivudine and NNRTIs, and in the Cameroonian study, another patient was found to be resistant to NNRTIs [7, 24] . In Malawi, 47 (11.8%) of 398 patients developed resistance to lamivudine and/or the NNRTIs nevirapine and efavirenz [10] . Two of the 20 patients in the study by Jack et al. [11] developed resistance to all 3 of the drugs in the antiretroviral regimen (didanosine, lamivudine, and efavirenz).
DISCUSSION
Through our review of the available literature, we found compelling evidence that HAART can be administered effectively in resource-limited settings in Africa. Nevertheless, we must be cautious about drawing conclusions about feasibility, because 26 of the 28 cohorts included !500 patients, and drug and monitoring costs are still out of reach for many.
Although we found adherence and drug resistance levels to be comparable to those of industrialized nations, there is difficulty in making direct comparisons between data from studies from industrialized nations and newly emerging data from studies from resource-poor areas. As recommendations regarding initiation of ART, effective first-and second-line regimens, virologic failure, and continuous therapy versus structured treatment interruptions continue to be debated, standards for clinical and immunologic outcomes will also evolve [34] . As a result, determining the outcome-based "success" of treatment programs in the developing world relies on complicated and changing data.
Methodological discrepancies between the African studies and those coming out of industrialized nations also account for the inability to easily compare data. The African cohorts were generally smaller and were studied for a short period, as opposed to ongoing natural history studies that are occurring in industrialized nations. Other information not provided by the studies reviewed, such as the coprevalence of non-HIVrelated morbidities, socioeconomic conditions, and genderrelated outcomes can also oblige cautiousness in making comparisons to cohorts in industrialized nations.
Features of program scale-up. According to the WHO guidelines, the first-line regimens most recommended for resource-limited settings are NNRTI-containing HAART regimens. The 2-NRTI backbone should consist of zidovudine or stavudine plus lamivudine. The primary NNRTIs to be used include efavirenz or nevirapine. NNRTI-containing HAART is claimed to be most suitable for developing countries because of its greater accessibility, lower cost, availability of fixed-dose regimens, efficacy, and low toxicity. Indeed, the vast majority of the studies reviewed provided this type of regimen for their cohorts. A few studies even employed WHO-prequalified, fixed-dose drug combinations, such as Combivir (zidovudine and lamivudine; GlaxoSmithKline), Maxivir (stavudine, lamivudine, and nevirapine; Cipla), and Triomune (stavudine, lamivudine, and nevirapine; Cipla).
Consistent monitoring based on WHO guidelines was implemented-and, at times, exceeded-in all studies reviewed. WHO recommends determination of the CD4 cell count, if possible, every 6-12 months, whereas viral load testing is not recommended because of its cost [5] . Nevertheless, consistent monitoring of clinical symptoms, blood cell counts, and toxicity is also advised under WHO guidelines. Most studies were able to conduct regular viral load testing, CD4 cell counts, clinical examinations, adherence monitoring, and, in a few cases, resistance surveillance. The implementation of such costly assessments at regular intervals might be a result of the fact that many of these studies took place under controlled research conditions. It is questionable, therefore, if this level of monitoring can be replicated in broader scale-up programs.
It is important to note that a number of new techniques are available to provide cost-efficient alternatives, including total lymphocyte count, complete blood cell count, and clinical monitoring only. In fact, the WHO and other studies from resourcelimited settings have cautiously endorsed using total lymphocyte count as a surrogate for CD4 cell count monitoring [5, 35] . However, because none of the 23 studies utilized surrogate methods, we cannot determine what levels of monitoring are necessary for HAART initiatives in Africa.
A possibility for monitoring adherence and retaining patients within longitudinal care programs is DOT. Only 1 study reviewed DOT, which was used specifically for the purpose of concurrent treatment of tuberculosis and HIV infection. In this case, DOT was a successful method to maintain adherence to treatment, especially with such a complicated regimen. Criticisms include DOT's significant logistical burden and minimal evidence that this method is superior to self-administration in resource-limited settings [36] .
Clinical/laboratory outcomes. Clinical outcomes among patients in the 28 studies were generally positive. Mortality rates were р13.7% in 22 of the 24 studies that reported these data. As for the 2 studies in which the mortality rate was 113.7%, one study in Senegal had been on-going for 3 years, naturally experiencing a greater number of deaths due to factors other than ineffective treatment. In the other study, patients were required to pay for their treatment, possibly compromising adherence and efficacy. Low incidences of opportunistic infections were also recorded for those studies that used these measurements.
The one study that examined the clinical efficacy of HAART among patients with tuberculosis and HIV infection proved that it is indeed possible for patients to benefit from HIV therapy, despite often presenting during late stages of illness. A recent study by Cassol et al. [37] also corroborates this finding, with South African HIV-infected patients with concurrent tuberculosis or Kaposi sarcoma experiencing greatly improved clinical outcomes after just 90 days of treatment.
A median of 21.2% of patients experienced drug toxicity, although there were few cases of grade 3 or 4 toxicity. The Swiss HIV cohort study found that 47% of patients presented with clinical adverse events associated with HAART use. The most common adverse events for "PI-sparing" regimens (which most of the African studies employed), were vomiting, mood disorders, elevated amylase level, elevated glucose level, lactic acidosis, neutropenia, and elevated alkaline phosphatase level [38] . Types of toxicity differed between the African and Swiss cohorts, most likely as a result of study design, observer biases, and lack of information about the severity and effects of toxicity that African patients experienced.
CD4 cell counts continued to improve throughout treatment periods, with a mean increase of 165.9 cells/mm 3 by mean time of 10.4 months. Among the 21 studies that reported viral load decreases, a median of 73% of patients had achieved undetectability by the ends of the studies. Both measurements fared well when compared with improvements noted in industrialized nations. A study from the United States reported a mean increase in the CD4 cell count of 160 cells/mm 3 and that a mean of 55% of patients had undetectable viral loads (р400 copies/mL) after 12 months [39] . Viral load rebounding was a problem in 3 studies [12, 13, 15] . In 2 studies, patients underwent treatment for a period of 112 months, and one of these cohorts paid for treatment. These 2 factors could indicate the possible development of drug resistance. Although the third study did not report these issues, it was the only one to use a nucleotide analogue regimen (zidovudine, lamivudine, and tenofovir). The WHO admits that it is still awaiting safety and efficacy data for this regimen [5] .
Of the studies that reported retention, the mean weighted retention was 79.8% over a mean duration of follow-up of 12.0 months, a high figure despite factors of cost, distance from clinic, side effects of treatment, and improving health status. Studies that did not offer data on retention may have included only patients who remained in the study from baseline to the end. This selection bias is problematic, because studies that have used this technique may have reported inflated outcomes without quantifying patients lost to follow-up.
Adherence. The majority of studies reporting adherence found that a high percentage of their subjects had adherence rates of 95% and often higher, closely comparing with the standard у95% rate for adherence in industrialized nations to produce optimal virologic outcomes [40] . Objective measures of adherence in industrialized nations found that patients take ∼70% of their prescribed antiretroviral medication, demonstrating that patients in Africa have similar, if not higher, adherence rates to those in industrialized nations [41] . In spite of these high levels of adherence, more specific criteria are needed in resource-limited settings to ensure that proper adherence is occurring.
Resistance. Among 5 studies that surveyed drug resistance, a mean weighted percentage of 10.1% of antiretroviral therapynaive African patients developed resistance to у1 antiretroviral drug. This outcome corresponds to a Swiss finding that 11% of newly HIV-infected Swiss patients manifest resistance to у1 drug [42] . The majority of people who would be eligible for antiretroviral therapy in Africa would be antiretroviral therapy naive.
Resistance to an NRTI was the most common resistance among the 5 studies. Because NRTIs are the established backbone for any combination therapy [43] , the likelihood of development of resistance is highest for this drug class. However, it is important to note that levels of resistance to NNRTIs were second to levels of resistance to NRTIs. Because these drugs were developed more recently, resistance is not as prevalent for them, but this may change with time. With the decreasing cost of these drugs, with recommendations for their use in HAART regimens in resource-limited settings, and with use to prevent mother-to-child transmission, resistance to NNRTIs may prove to be a greater problem in the near future.
Conclusions. This review of 28 studies analyzing ART programs in Africa provides promising evidence for the administration of HIV treatment in resource-poor settings. Essentially all studies reported high rates of adherence and optimistic outcomes. The WHO guidelines provide an appropriate framework, as reflected by the ability for the studies reviewed to employ recommended regimens and regular monitoring strategies. Of note is the fact that many of the studies reviewed exceeded WHO standards in terms of clinical and laboratory monitoring, and we might expect less ideal results in nonresearch conditions.
The results demonstrated by this review have strong implications for current treatment initiatives, including those administered by national governments and the President's Emergency Plan for AIDS Relief. Although these initiatives possess potential for success, they will require continuous surveillance, to determine long-term feasibility and impact. Efforts to publicize the clinical and operational successes and failures must continue to develop crucial improvements for lasting success.
